Targeted cancer therapies represent a significant advancement in oncology, focusing on delivering therapeutic agents directly to cancer cells while sparing healthy tissue. A key technology enabling this precision is radiopharmaceutical therapy, which utilizes radioisotopes attached to tumor-specific targeting molecules. Essential to this process is the chelating agent DOTA (1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, CAS 60239-18-1), which securely holds the radioisotope.

DOTA's unique macrocyclic structure allows it to form extremely stable complexes with a variety of medically important radionuclides, including alpha and beta emitters like Yttrium-90 (90Y) and Lutetium-177 (177Lu). This stability is critical for radiopharmaceutical efficacy and safety, ensuring the radioisotope remains bound to the targeting molecule throughout its journey to the tumor and during its therapeutic action. Without such robust chelation, the radioisotope could be released prematurely, leading to increased toxicity and reduced therapeutic effect. DOTA's chemical properties, including its molecular formula C16H28N4O8 and molecular weight of 404.42, contribute to its effectiveness in these high-stakes applications.

NINGBO INNO PHARMCHEM CO.,LTD. is a leading manufacturer and supplier of DOTA, providing the high-purity pharmaceutical intermediate (98%min) that is essential for the development of these advanced cancer therapies. We understand the critical nature of supplying reliable materials for life-saving treatments. Our commitment to quality, competitive pricing, and a stable supply chain from China makes us a preferred partner for pharmaceutical companies and research institutions worldwide. If you are looking to purchase DOTA for your radiopharmaceutical development, NINGBO INNO PHARMCHEM is your trusted source.

The precise molecular structure of DOTA, appearing as a white solid, is key to its function. By partnering with us, you ensure access to a consistent and high-quality supply of this vital chelator. We invite you to contact NINGBO INNO PHARMCHEM to discuss your DOTA requirements and discover how our commitment to excellence can support your efforts in developing next-generation targeted cancer therapies.